Rocket PharmaceuticalsRCKT
RCKT
About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Employees: 299
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
152% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 23
113% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 45
19% more funds holding
Funds holding: 189 [Q3] → 224 (+35) [Q4]
1.41% more ownership
Funds ownership: 101.68% [Q3] → 103.1% (+1.41%) [Q4]
9% less call options, than puts
Call options by funds: $2.09M | Put options by funds: $2.28M
19% less capital invested
Capital invested by funds: $1.71B [Q3] → $1.38B (-$328M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
97%
upside
Avg. target
$42
444%
upside
High target
$54
608%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Needham Gil Blum 18% 1-year accuracy 29 / 158 met price target | 450%upside $42 | Buy Reiterated | 9 Apr 2025 |
BMO Capital Kostas Biliouris 6% 1-year accuracy 1 / 17 met price target | 555%upside $50 | Outperform Initiated | 12 Mar 2025 |
Scotiabank Greg Harrison 33% 1-year accuracy 14 / 42 met price target | 582%upside $52 | Sector Outperform Maintained | 3 Mar 2025 |
Goldman Sachs Richard Law 63% 1-year accuracy 5 / 8 met price target | 97%upside $15 | Neutral Maintained | 3 Mar 2025 |
Canaccord Genuity Whitney Ijem 34% 1-year accuracy 15 / 44 met price target | 372%upside $36 | Buy Maintained | 3 Mar 2025 |
Financial journalist opinion
Positive
Seeking Alpha
2 weeks ago
Rocket Pharma Out Of Orbit, But Ready For Relaunch
Rocket Pharmaceuticals' gene therapies offer long-term effects for cardiovascular and hematology diseases, addressing severe unmet needs like Danon Disease, which currently requires heart transplants. The near-term outlook driven by clinical milestones for RP-A601, RP-A501, and potential Kresladi approval, with the current share price at $5 offering significant value. Rocket has $372M in cash, funding operations through 1H 2026, but will likely need financing post-positive data readout or Kresladi approval for commercialization.
Neutral
Business Wire
3 weeks ago
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that management will participate in the 24th Annual Needham Virtual Healthcare Conference taking place on April 8, 2025. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat at 8:45 a.m. ET on Tuesday, April 8. A webcast of the fire.
Neutral
Zacks Investment Research
2 months ago
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
Neutral
Business Wire
2 months ago
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the fourth quarter and year ended December 31, 2024. “In 2024, we made strong progress in advancing our gene therapy pipeline, underscored by the New England Journal of Medicine publication of the Phase 1 study of.
Positive
Seeking Alpha
2 months ago
Rocket Pharma Is A Buy At These Prices With Promising Data
Rocket Pharmaceuticals, Inc.'s RP-L201 for LAD-I faces FDA rejection but shows promising data; potential approval could unlock a $350M market. RP-L102 for Fanconi Anemia and RP-A501 for Danon Disease show strong clinical data, indicating significant market potential. Financially, Rocket Pharma has a limited cash runway of 2–4 quarters, dependent on FDA approvals and successful public offerings.
Negative
Zacks Investment Research
3 months ago
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Benzinga
3 months ago
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
Business Wire
3 months ago
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, in San Francisco, California. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Monday, January 13, at 3:45 p.m. PT and host investor meetings throu.
Positive
Investopedia
4 months ago
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'
Shares of Rocket Pharmaceuticals (RCKT) jumped 5.5% intraday Wednesday as Jefferies initiated coverage of the biotech company with a "buy" rating on optimism about the experimental drugs in its pipeline. Jefferies also set a price target of $29, more than double its current value.
Neutral
Business Wire
4 months ago
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today the pricing of an upsized underwritten public offering of 13,200,000 shares of its common stock at a public offering price of $12.50 per share. The gross proceeds to Rocket from the offering, before deducting underwriting discounts and commissions and offer.
Charts implemented using Lightweight Charts™